Brahms pct

After ICU admission, a 5 mL peripheral venous blood sample was collected from each patient via venipuncture. The collected samples were then centrifuged at 3500 r min for 5 min, and the resulting serum samples were stored at a temperature of -80 °C for subsequent analyses. To determine serum CRP levels, we used a commercially available CRP test kit (Mindray, Shenzhen, China) based on the immunoturbidimetric method. IL-6 and PCT levels were measured by electrochemiluminescence using the Elecsys IL-6 and BRAHMS PCT (Roche) kits, respectively. Serum ChE levels were determined using a kit from Shanghai Gao Chuang Medical Technology, Shanghai, China based on the butyrylthiocholine method.

All of the biomarkers were measured in a central laboratory, and all of the samples were labeled using study identification numbers without personal identifiers or clinical conditions. PCT was measured by Elecsys BRAHMS PCT (Roche Diagnostics GmbH, Germany; normal range, ≤0.05 μg/L). CRP was measured by an immunoenzyme analyzer (Hitachi 917, Tokyo, Japan; normal range, ≤5 mg/L). WBC counts were measured using an XE4000i automatic hemocyte analyzer. Blood samples for the purpose of study were collected only within 1 h after ICU admission, and clinicians decided the time and frequency of testing according to the actual clinical situation during the ICU stay.

Blood was collected from all patients to measured plasma biomarkers such as OXA, C-reactive protein (CRP), procalcitonin, presepsin and NGAL at the ICU admission. Plasma CRP, procalcitonin, and presepsisin were measured in Clinical Laboratory Department in our hospital. Plasma CRP was measured using JCA-BM6070 Biomajesty (JEOL, Tokyo) and the lower limit of detection was 0.02 mg/dL. Plasma presepsin were determined with a compact automated immunoanalyzer (PATHFAST; Mitsubishi Chemical Medience Corporation, Tokyo, Japan) using a chemiluminescent enzyme immunoassay. The lower limit of detection was 20 pg/mL. Plasma procalcitonin were measured via an electrochemiluminescent immunoassay using Elecsys reagents, the Elecsys BRAHMS PCT, and a Cobas e411 (Roche Diagnostics, Tokyo, Japan), according to the manufacturer’s instructions. The lower limit of detection was 0.02 ng/mL. Plasma OXA and NGAL were quantified using ELISA kits (OXA: Peninsula Laboratories International, San Carlos, CA, USA, NGAL: BioPorto Diagnostics A/S, Demark) in our departmental laboratory. The orexin A and NGAL assays were carried out in duplicate and mean intra- and inter-assay coefficient of variation were 5% and 10% and 14% and 14%, respectively.